A Study of Psilocybin for PTSD - Trial NCT06407635
Access comprehensive clinical trial information for NCT06407635 through Pure Global AI's free database. This Phase 1 trial is sponsored by Johns Hopkins University and is currently Not yet recruiting. The study focuses on Post Traumatic Stress Disorder. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Johns Hopkins University
Timeline & Enrollment
Phase 1
May 01, 2024
May 01, 2027
Primary Outcome
Incidence of Adverse Events,Columbia Suicide Severity Rating Scale (C-SSRS),Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual (DSM)-5 (CAPS-5),Ecological Momentary Assessment (EMA) of PTSD Checklist for DSM-5 (PCL-5),World Health Organization Quality of Life Brief Version (WHOQOL-BREF)
Summary
The proposed open-label, controlled study at the Johns Hopkins Center for Psychedelic and
 Consciousness Research (CPCR) will test the following primary hypotheses in adult patients
 with chronic PTSD who are currently taking a serotonin reuptake inhibitor: psilocybin therapy
 will be feasible and safe for participants, significantly remediate PTSD symptoms, and
 enhance wellbeing and quality of life. In addition, the study will examine whether elements
 of evidence-based trauma-focused psychotherapy enhance treatment response when paired with
 psilocybin.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06407635
Non-Device Trial